Evidence map›Paper›PMID 31856060›Full record

ReviewChinese medical journal2019

Involvement of hydrogen sulfide in the progression of renal fibrosis.

Yu Wang, Qi-Qi Xing, Jing-Ke Tu, Wen-Bin Tang, Xiang-Ning Yuan, Yan-Yun Xie, Wei Wang, Zhang-Zhe Peng, Ling Huang, Hui Xu and 4 more

Open access · goldAbstract readReview
In one paragraph

Review in Chinese medical journal, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.2field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Review
  8. Exogenous HCardiovascular toxicology · 2022
    Article
  9. Article
  10. Article
  11. Review
  12. PSC-MSC-Derived Exosomes Protect against Kidney FibrosisInternational journal of stem cells · 2021
    Article
  13. HPharmacological research · 2020
    Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Yu WangReproductive Medicine Center, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Qi-Qi XingDivision of Orthopedics, Department of Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Jing-Ke TuRegenerative Medicine Clinic, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300041, China.
Wen-Bin TangDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Xiang-Ning YuanDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Yan-Yun XieDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Wei WangDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Zhang-Zhe PengDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Ling HuangDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Hui XuDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Jiao QinDivision of Nephrology, Department of Internal Medicine, Changsha Central Hospital, Changsha, Hunan 410008, China.
Xiang-Cheng XiaoDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Li-Jian TaoDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Qiong-Jing YuanDivision of Nephrology, Department of Internal Medicine, Xiangya Hospital, Central South University, Changsha, Hunan 410008, China.
Central South University · CNXiangya Hospital Central South University · CNInstitute of Hematology & Blood Diseases Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveRenal fibrosis is the most common manifestation of chronic kidney disease (CKD). Noting that existing treatments of renal fibrosis only slow disease progression but do not cure it, there is an urgent need to identify novel therapies. Hydrogen sulfide (H2S) is a newly discovered endogenous small gas signaling molecule exerting a wide range of biologic actions in our body. This review illustrates recent experimental findings on the mechanisms underlying the therapeutic effects of H2S against renal fibrosis and highlights its potential in future clinical application. DATA SOURCES: Literature was collected from PubMed until February 2019, using the search terms including "Hydrogen sulfide," "Chronic kidney disease," "Renal interstitial fibrosis," "Kidney disease," "Inflammation factor," "Oxidative stress," "Epithelial-to-mesenchymal transition," "H2S donor," "Hypertensive kidney dysfunction," "Myofibroblasts," "Vascular remodeling," "transforming growth factor (TGF)-beta/Smads signaling," and "Sulfate potassium channels." STUDY SELECTION: Literature was mainly derived from English articles or articles that could be obtained with English abstracts. Article type was not limited. References were also identified from the bibliographies of identified articles and the authors' files.

resultsThe experimental data confirmed that H2S is widely involved in various renal pathologies by suppressing inflammation and oxidative stress, inhibiting the activation of fibrosis-related cells and their cytokine expression, ameliorating vascular remodeling and high blood pressure, stimulating tubular cell regeneration, as well as reducing apoptosis, autophagy, and hypertrophy. Therefore, H2S represents an alternative or additional therapeutic approach for renal fibrosis.

conclusionsWe postulate that H2S may delay the occurrence and progress of renal fibrosis, thus protecting renal function. Further experiments are required to explore the precise role of H2S in renal fibrosis and its application in clinical treatment.

Indexed as

AnimalsDisease ProgressionFibrosisHumansHydrogen SulfideKidneyHydrogen Sulfide

Identifiers

PMID31856060
PMCPMC6940064
OpenAlexW3004274337

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.